Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer

F Kraeber-Bodéré, D M Goldenberg, J F Chatal, J Barbet, F Kraeber-Bodéré, D M Goldenberg, J F Chatal, J Barbet

No abstract available

Keywords: Pretargeted radioimmunotherapy; calcitonin; medullary thyroid cancer.

Figures

FIGURE 1
FIGURE 1
Imaging by (A) fluorodeoxyglucose positron-emission tomography and (B) immunoscintigraphy in a patient having medullary thyroid carcinoma with cardiac metastasis. The images show good tumour targeting with both radiopharmaceuticals.

References

    1. Tubiana M, Milhaud G, Coutris G, Lacour J, Parmentier C, Bok B. Medullary carcinoma and thyrocalcitonin. Br Med J. 1968;4:87–9.
    1. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029–34.
    1. Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg. 2008;32:754–65.
    1. Bergholm U, Bergström R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer. 1997;79:132–8.
    1. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The getc Study Group. Groupe d’étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) 1998;48:265–73.
    1. Miccoli P, Minuto MN, Ugolini C, et al. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer. 2007;14:1099–105.
    1. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–48.
    1. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the eortc Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033–41.
    1. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic ret oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682–7.
    1. Ito Y, Yoshida H, Tomoda C, et al. Expression of Cdc25b and Cdc25a in medullary thyroid carcinoma: Cdc25b expression level predicts a poor prognosis. Cancer Lett. 2005;229:291–7.
    1. Tisell LE, Oden A, Muth A, et al. The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer. 2003;89:2093–7.
    1. Barbet J, Campion L, Kraeber–Bodéré F, Chatal JF on behalf of the gte Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077–84.
    1. Chatal JF, Campion L, Kraeber–Bodéré F, et al. on behalf of the French Endocrine Tumor Group. Survival improvement in patients with medullary thyroid carcinoma who undergo pre-targeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705–11.
    1. Oudoux A, Salaun PY, Bournaud C, et al. Sensitivity and prognostic value of positron emission tomography with F-18–fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590–7.
    1. Mirallié E, Vuillez JP, Bardet S, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779–88.
    1. Barbet J, Kraeber-Bodéré F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999;14:153–66.
    1. Bardiès M, Bardet S, Faivre–Chauvet A, et al. Bispecific antibody and iodine-131–labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med. 1996;37:1853–9.
    1. Kraeber–Bodéré F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131–labeled bivalent hapten: preliminary results of a phase i/ii clinical trial. Clin Cancer Res. 1999;5(suppl):3190s–8s.
    1. Kraeber–Bodéré F, Faivre–Chauvet A, Ferrer L, et al. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen × anti-hapten bispecific antibody–mediated pretargeting of iodine-131–labeled hapten in a phase i radioimmunotherapy trial. Clin Cancer Res. 2003;9:3973S–81S.
    1. Kraeber–Bodéré F, Rousseau C, Bodet–Milin C, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase i optimization clinical trial. J Nucl Med. 2006;47:247–55.
    1. Iten F, Müller B, Schindler C, et al. Response to [90Yttrium–dota]–toc treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase ii clinical trial. Clin Cancer Res. 2007;13:6696–702.
    1. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, De-Conti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155–60.
    1. Fromigué J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:2496–9.
    1. Lorenz K, Brauckhoff M, Behrmann C, et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery. 2005;138:986–93.
    1. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996;81:1619–22.
    1. Gross DJ, Munter G, Bitan M, et al. on behalf of the Israel Glivec in Solid Tumors Study Group. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for C-kit or pdgf-r. Endocr Relat Cancer. 2006;13:535–40.
    1. de Groot JW, Zonnenberg BA, van Ufford–Mannesse PQ, et al. A phase ii trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3466–9.
    1. Frank–Raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007;157:215–20.
    1. Cohen EE, Vokes EE, Rosen LS, et al. A phase ii study of axitinib (AG-013736 [ag]) in patients (pts) with advanced thyroid cancers [abstract 6008] [accessed July 24, 2009]];Proc Am Soc Clin Oncol. 2007 25 [Available online at: .
    1. Kober F, Hermann M, Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer [abstract 14065] [accessed July 24, 2009]];Proc Am Soc Clin Oncol. 2007 25 [Available online at: .
    1. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase ii trial [abstract 6018] [accessed July 24, 2009]];Proc Am Soc Clin Oncol. 2007 25 [Available online at: .
    1. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22–32.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅